Jump Main Menu. Go directly to the main content

Sección de idiomas

EN

Fin de la sección de idiomas

Access / Registration

Sección de utilidades

Fin de la sección de utilidades

MENU

Start of main content

Research centres : Epigenetics and Cancer Biology Program. Bellvitge Biomedical Research Institute (IDIBELL). Barcelona. (Spain) Programa de Epigenética y Biología del Cáncer. Institut d'Investigació Biomédica de Bellvitge (IDIBELL). Barcelona.

Manel Esteller Badosa

He was born in Sant Boi de Llobregat, Barcelona, 1968, and graduated with Honours in Medicine from the University of Barcelona in 1992, where he also obtained his Ph.D. specialising in Molecular Genetics of Endometrial Carcinoma in 1996. He was Research Fellow in the School of Biological and Medical Sciences at the University of St. Andrews (Scotland, United Kingdom), where his research focused on the study of molecular genetics in hereditary breast cancer. From 1997 to 2001, Esteller was a Postdoctoral Researcher and Research Associate at the School of Medicine at Johns Hopkins University (Baltimore, USA) where he studied DNA methylation and its relationship to cancer in humans.

His results have been instrumental in establishing that hypermethylation of tumour suppressor genes is a hallmark of human tumours. From October 2001 to September 2008, Manel Esteller led the Cancer Epigenetics Laboratory at the CNIO. During this time he was devoted to the investigation of alterations in DNA methylation, histone and chromatin modifications and their contribution to cancer in humans. Since October 2008, Dr. Esteller has been the Director of the Epigenetics and Cancer Biology Programme of the Bellvitge Institute for Biomedical Research (IDIBELL) in Barcelona, Professor of Genetics at the Faculty of Medicine at the University of Barcelona and ICREA Research Professor.

His current research focuses on the establishment of epigenomic maps of normal and transformed cells, the study of epigenetic modifications and non-coding RNAs and the epigenetic development of new drugs to treat cancer. Dr. Esteller has authored over two hundred and fifty original manuscripts accredited in the field of biomedical sciences, is a member of numerous international scientific societies and publications and a reviewer for several journals and sponsoring agencies. He has received numerous awards including the European School of Medical Oncology Award (1999), Outstanding Young Investigator of the European Association for Cancer Research (2000), Beckman-Coulter Award (2006), Debiopharm-EPFL Award (2008), Josef Steiner Cancer Research Award (2009), Preclinical Biomedical Research Award from the Lilly Endowment (2009) and the Carmen and Severo Ochoa Foundation Research Award (2009). 

End of main content